Charles River Laboratories International Management
Management criteria checks 4/4
Charles River Laboratories International's CEO is Jim Foster, appointed in Jan 1991, has a tenure of 33.25 years. total yearly compensation is $14.10M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $63.00M. The average tenure of the management team and the board of directors is 5.3 years and 10 years respectively.
Key information
Jim Foster
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | 10.4% |
| CEO tenure | 33.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5.3yrs |
| Board average tenure | 10yrs |
Recent management updates
Recent updates
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Charles River raised to Buy at Jefferies on prospects for animal studies
Sep 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 30 2023 | n/a | n/a | US$475m |
| Sep 30 2023 | n/a | n/a | US$475m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$496m |
| Dec 31 2022 | US$13m | US$1m | US$486m |
| Sep 24 2022 | n/a | n/a | US$436m |
| Jun 25 2022 | n/a | n/a | US$443m |
| Mar 26 2022 | n/a | n/a | US$422m |
| Dec 25 2021 | US$14m | US$1m | US$391m |
| Sep 25 2021 | n/a | n/a | US$397m |
| Jun 26 2021 | n/a | n/a | US$396m |
| Mar 27 2021 | n/a | n/a | US$375m |
| Dec 26 2020 | US$13m | US$1m | US$364m |
| Sep 26 2020 | n/a | n/a | US$301m |
| Jun 27 2020 | n/a | n/a | US$271m |
| Mar 28 2020 | n/a | n/a | US$248m |
| Dec 28 2019 | US$18m | US$1m | US$252m |
| Sep 28 2019 | n/a | n/a | US$231m |
| Jun 29 2019 | n/a | n/a | US$219m |
| Mar 30 2019 | n/a | n/a | US$227m |
| Dec 29 2018 | US$14m | US$1m | US$225m |
| Sep 29 2018 | n/a | n/a | US$135m |
| Jun 30 2018 | n/a | n/a | US$128m |
| Mar 31 2018 | n/a | n/a | US$129m |
| Dec 30 2017 | US$13m | US$1m | US$123m |
Compensation vs Market: Jim's total compensation ($USD14.10M) is about average for companies of similar size in the US market ($USD13.52M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Foster (72 yo)
33.3yrs
Tenure
US$14,096,923
Compensation
Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer since 1992 and serves as its President since 1991....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 33.3yrs | US$14.10m | 0.51% $ 63.0m | |
| Corporate Executive VP & CFO | 1.9yrs | US$3.81m | 0.00053% $ 65.4k | |
| Corporate Executive VP & COO | 2.4yrs | US$4.99m | 0.080% $ 9.8m | |
| Corporate Executive Vice President of Corporate Development & Strategy | 13.3yrs | US$3.06m | 0.026% $ 3.2m | |
| Corporate Executive Vice President of Community Relations | 7.5yrs | US$2.91m | 0.044% $ 5.5m | |
| Corporate Senior VP & Chief Accounting Officer | 7yrs | no data | 0.0081% $ 1.0m | |
| Corporate Senior VP & Chief Scientific Officer | 2.4yrs | no data | no data | |
| Corporate Senior VP & Chief Information Officer | 2.8yrs | no data | no data | |
| Corporate Vice President of Investor Relations | no data | no data | no data | |
| Corporate Senior VP | 3.6yrs | no data | no data | |
| Corporate Vice President & Chief Communications Officer | no data | no data | no data | |
| Chief Marketing Officer & Corporate Senior VP | 8.3yrs | no data | no data |
5.3yrs
Average Tenure
51.5yo
Average Age
Experienced Management: CRL's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 35.3yrs | US$14.10m | 0.51% $ 63.0m | |
| Independent Director | 16.3yrs | US$341.02k | 0.13% $ 15.5m | |
| Independent Director | 13.3yrs | US$339.77k | 0.045% $ 5.5m | |
| Lead Independent Director | 21.3yrs | US$371.02k | 0.0097% $ 1.2m | |
| Independent Director | 4.5yrs | US$346.02k | 0.0053% $ 658.5k | |
| Independent Director | 13.3yrs | US$346.02k | 0.060% $ 7.4m | |
| Independent Director | 1.3yrs | US$437.78k | 0.00048% $ 59.2k | |
| Director | 6.8yrs | US$336.02k | 0.020% $ 2.5m | |
| Independent Director | 15.5yrs | US$339.77k | 0.014% $ 1.8m | |
| Independent Director | 4.2yrs | US$339.77k | 0.0035% $ 431.6k | |
| Independent Director | 3.5yrs | US$324.77k | 0.0035% $ 436.5k | |
| Independent Director | less than a year | no data | 0% $ 0 |
10.0yrs
Average Tenure
67.5yo
Average Age
Experienced Board: CRL's board of directors are seasoned and experienced ( 10 years average tenure).